← Leaderboards
Douglas G McNeel
University Of Wisconsin-Madison
$9,457,366
Attributed
$9,457,366
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,772,062 · 12
By mechanism
P50$7,379,303 · 3
R01$3,296,563 · 2
T32$2,196,002 · 1
P01$1,588,567 · 2
K23$708,696 · 1
R21$590,625 · 1
Top collaborators
- David F Jarrard3 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- David F Jarrard$5,385,495
- Joseph T. Barbieri$22,361,133
- Erin Marie Theisen$100,044
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateResponseClinical TrialsTumorAndrogen ReceptorAntigensVaccinesTissuesProstatic NeoplasmsMissionNational Cancer InstituteCancer VaccinesMalignant NeoplasmsProstateMetastatic Prostate CancerResistanceImmunizationDna VaccinesMouse ModelCellsPhase I Clinical TrialsCancer TherapyImmunotherapyDesign
Grant awards (38)
University of Wisconsin Prostate SPORE$2,167,946
P50 · FY2025 · CA
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer$366,237
P50 · FY2025 · CA · contact PI
University of Wisconsin Prostate SPORE$2,085,688
P50 · FY2024 · CA
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer$351,669
P50 · FY2024 · CA · contact PI
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation$300,190
P01 · FY2024 · CA · contact PI
University of Wisconsin Prostate SPORE$2,061,062
P50 · FY2023 · CA
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer$346,701
P50 · FY2023 · CA · contact PI
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation$319,121
P01 · FY2023 · CA · contact PI
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation$319,122
P01 · FY2022 · CA · contact PI
Effective Anti-Tumor Vaccination - Targeting Checkpoint Regulation at the Time of T-cell Activation$349,988
R01 · FY2021 · CA · contact PI
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation$325,547
P01 · FY2021 · CA · contact PI
Effective Anti-Tumor Vaccination - Targeting Checkpoint Regulation at the Time of T-cell Activation$349,988
R01 · FY2020 · CA · contact PI
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation$324,587
P01 · FY2020 · CA · contact PI
Effective Anti-Tumor Vaccination - Targeting Checkpoint Regulation at the Time of T-cell Activation$339,487
R01 · FY2019 · CA · contact PI
Effective Anti-Tumor Vaccination - Targeting Checkpoint Regulation at the Time of T-cell Activation$349,988
R01 · FY2018 · CA · contact PI
Effective Anti-Tumor Vaccination - Targeting Checkpoint Regulation at the Time of T-cell Activation$349,988
R01 · FY2017 · CA · contact PI
Physician Scientist Training in Cancer Medicine$410,197
T32 · FY2014 · CA · contact PI
Androgen Receptor Targeted Vaccines for Prostate Cancer$342,928
R01 · FY2014 · CA · contact PI
Androgen Receptor Targeted Vaccines for Prostate Cancer$332,331
R01 · FY2013 · CA · contact PI
Physician Scientist Training in Cancer Medicine$309,704
T32 · FY2013 · CA · contact PI
Physician Scientist Training in Cancer Medicine$350,330
T32 · FY2012 · CA · contact PI
Androgen Receptor Targeted Vaccines for Prostate Cancer$304,715
R01 · FY2012 · CA · contact PI
Androgen Receptor Targeted Vaccines for Prostate Cancer$284,180
R01 · FY2011 · CA · contact PI
Physician Scientist Training in Cancer Medicine$233,162
T32 · FY2011 · CA · contact PI
Physician Scientist Training in Cancer Medicine$323,789
T32 · FY2010 · CA · contact PI
Androgen receptor targeted vaccines for prostate cancer$292,970
R01 · FY2010 · CA · contact PI
Physician Scientist Training in Cancer Medicine$303,291
T32 · FY2009 · CA · contact PI
Pilot trial of a DNA vaccine encoding PAP in patients with prostate cancer$294,739
R21 · FY2009 · CA · contact PI
Pilot trial of a DNA vaccine encoding PAP in patients with prostate cancer$295,886
R21 · FY2008 · CA · contact PI
Physician Scientist Training in Cancer Medicine$265,529
T32 · FY2008 · CA · contact PI
PHASE I STUDY OF A DNA-BASED VACCINE TARGETING PROSTATIC ACID PHOSPHATASE (PAP)$1,445
M01 · FY2007 · RR · contact PI
A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase$145,534
K23 · FY2006 · RR · contact PI
PHASE I STUDY OF A DNA-BASED VACCINE TARGETING PROSTATIC ACID PHOSPHATASE$10,861
M01 · FY2006 · RR · contact PI
A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase$145,534
K23 · FY2005 · RR
A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase$145,534
K23 · FY2004 · RR
A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase$133,804
K23 · FY2003 · RR
Pilot -- Identification of Antigens of Prostate$0
P50 · FY2003 · DK
A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase$138,290
K23 · FY2002 · RR